Pantec Biosolutions Receives CHF 20m Investment from StemCell Holding

Pantec Biosolutions AG, a Ruggell, Liechtenstein-based drug delivery company specialised in using laser microporation technology to deliver large molecular weight drugs into the epidermis for local or systemic uptake, received a CHF 20m investment from the StemCell Holding AG, an Austrian private equity firm focused on the life sciences sector.
The funds will be used to drive the development, approval and market launch of its proprietary P.L.E.A.S.E.® (Painless Laser Epidermal System) platform that enables needle-free and painless administration of biopharmaceutical drugs, in varying and individualised dosages, through partnered patch technology.
In conjunction with the investment, Dr. Manfred Asamer, CEO of Asamer Holding AG, and Dr. Werner Lanthaler, the current CEO of Evotec and the ex-CFO of Intercell, will join the company’s board.

Join the discussion